These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 10742335)

  • 1. The critical role of population-based epidemiology in cost-effectiveness research.
    Joffe S; Lieu TA; Escobar GJ
    Pediatrics; 2000 Apr; 105(4 Pt 1):862-3. PubMed ID: 10742335
    [No Abstract]   [Full Text] [Related]  

  • 2. The pitfalls of using managed care databases in cost-effectiveness research.
    Groothuis JR
    Pediatrics; 1999 Nov; 104(5 Pt 1):1124-5. PubMed ID: 10545557
    [No Abstract]   [Full Text] [Related]  

  • 3. Respiratory syncytial virus and premature infants born at 32 weeks' gestation or earlier: hospitalization and economic implications of prophylaxis.
    Stevens TP; Sinkin RA; Hall CB; Maniscalco WM; McConnochie KM
    Arch Pediatr Adolesc Med; 2000 Jan; 154(1):55-61. PubMed ID: 10632251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Small budget impact is a result of flawed assumptions and ignores questionable cost-effectiveness for RSV prophylaxis.
    Hampp C; Kauf TL; Winterstein AG
    Value Health; 2010 Aug; 13(5):684. PubMed ID: 20412545
    [No Abstract]   [Full Text] [Related]  

  • 5. Development of local guidelines for prevention of respiratory syncytial viral infections.
    Hall CB; Stevens TP; Swantz RJ; Sinkin RA; McBride JT
    Pediatr Infect Dis J; 1999 Oct; 18(10):850-3. PubMed ID: 10530578
    [No Abstract]   [Full Text] [Related]  

  • 6. Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants.
    Joffe S; Ray GT; Escobar GJ; Black SB; Lieu TA
    Pediatrics; 1999 Sep; 104(3 Pt 1):419-27. PubMed ID: 10469764
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of health economics to guide drug development decisions: Determining optimal values for an RSV-vaccine in a model-based scenario-analytic approach.
    Bos JM; Rietveld E; Moll HA; Steyerberg EW; Luytjes W; Wilschut JC; de Groot R; Postma MJ
    Vaccine; 2007 Sep; 25(39-40):6922-9. PubMed ID: 17707959
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The 2009 COID recommendations for RSV prophylaxis: issues of efficacy, cost, and evidence-based medicine.
    Krilov LR; Weiner LB; Yogev R; Fergie J; Katz BZ; Henrickson KJ; Welliver RC
    Pediatrics; 2009 Dec; 124(6):1682-4. PubMed ID: 19948634
    [No Abstract]   [Full Text] [Related]  

  • 9. Comments on palivizumab (Synagis).
    Moler FW; Brown RW; Faix RG; Gilsdorf JR
    Pediatrics; 1999 Feb; 103(2):495-7. PubMed ID: 9925848
    [No Abstract]   [Full Text] [Related]  

  • 10. Economic evaluation of possible prevention of RSV-related hospitalizations in premature infants in Germany.
    Roeckl-Wiedmann I; Liese JG; Grill E; Fischer B; Carr D; Belohradsky BH
    Eur J Pediatr; 2003 Apr; 162(4):237-44. PubMed ID: 12647196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of immunoprophylaxis in the reduction of disease attributable to respiratory syncytial virus.
    Meissner HC; Bocchini JA; Brady MT; Hall CB; Kimberlin DW; Pickering LK
    Pediatrics; 2009 Dec; 124(6):1676-9. PubMed ID: 19948632
    [No Abstract]   [Full Text] [Related]  

  • 12. Cost-effectiveness of palivizumab for respiratory syncytial virus infection in high-risk children, based on long-term epidemiologic data from Austria.
    Resch B; Sommer C; Nuijten MJ; Seidinger S; Walter E; Schoellbauer V; Mueller WD
    Pediatr Infect Dis J; 2012 Jan; 31(1):e1-8. PubMed ID: 21960187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of respiratory syncytial virus (RSV) risk factors and cost implications of immunoprophylaxis to infants 32 to 35 weeks gestation for health plans in the United States.
    Krilov LR; Palazzi DL; Fernandes AW; Klein RW; Mahadevia PJ
    Value Health; 2010; 13(1):77-86. PubMed ID: 19706010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population-Attributable Risk of Risk Factors for Recurrent Wheezing in Moderate Preterm Infants During the First Year of Life.
    Blanken MO; Korsten K; Achten NB; Tamminga S; Nibbelke EE; Sanders EA; Smit HA; Groenwold RH; Bont L;
    Paediatr Perinat Epidemiol; 2016 Jul; 30(4):376-85. PubMed ID: 27199198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prophylaxis against respiratory syncytial virus in high-risk infants: administration of immune globulin and epidemiological surveillance of infection.
    Handal G; Logvinoff MM; Zegarra N; Allen L; Jesurun A; Levin G; Thida A
    Tex Med; 2000 May; 96(5):58-61. PubMed ID: 10843015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of palivizumab on expected costs of respiratory syncytial virus infection in preterm infants: potential for savings.
    Marchetti A; Lau H; Magar R; Wang L; Devercelli G
    Clin Ther; 1999 Apr; 21(4):752-66. PubMed ID: 10363740
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness analysis of palivizumab as respiratory syncytial virus prophylaxis in preterm infants in Sweden.
    Neovius K; Buesch K; Sandström K; Neovius M
    Acta Paediatr; 2011 Oct; 100(10):1306-14. PubMed ID: 21477089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness analysis of palivizumab in premature infants without chronic lung disease.
    Elhassan NO; Sorbero ME; Hall CB; Stevens TP; Dick AW
    Arch Pediatr Adolesc Med; 2006 Oct; 160(10):1070-6. PubMed ID: 17018467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population based external validation of a European predictive model for respiratory syncytial virus hospitalization of premature infants born 33 to 35 weeks of gestational age.
    Stensballe LG; Fullarton JR; Carbonell-Estrany X; Simões EA
    Pediatr Infect Dis J; 2010 Apr; 29(4):374-6. PubMed ID: 20016397
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention of respiratory syncytial virus infection with palivizumab.
    Thomas M; Bedford-Russell A; Sharland M
    Monaldi Arch Chest Dis; 2000 Aug; 55(4):333-8. PubMed ID: 11057088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.